Clinicians should evaluate the familial risk of metabolic disorders and monitor metabolic parameters (e.g., body mass index, blood glucose and insulin levels, dietary habits, physical activity, and sleep patterns) throughout treatment, particularly when prescribing potentially obesogenic agents, to better understand and mitigate their potential impact on OCD severity and progression and general health. The gene discussed is INS; the disease is metabolic disease.